Type 2
diabetes is a chronic condition and is the
most common form of diabetes. High levels of glucose are a characteristic
feature. The body might become resistant to insulin or may not produce enough
amounts. Due to abnormal insulin functioning, glucose is concentrated in the
blood leading to elevated levels and hence causing type 2 diabetes. Symptoms
include fatigue, weight issues, vision deficits and various other effects. Risk
factors include family history, age, obesity, physical inactivity and high
blood pressure. This condition is handled by lifestyle alterations and regular
medications.
Report Highlights
Pharmaceutical and Healthcare latest pipeline
guide Type 2 Diabetes - Pipeline Review, H1 2017, provides comprehensive
information on the therapeutics under development for Type 2 Diabetes
(Metabolic Disorders), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and latest news and press
releases.
Browse Detail Report With TOC @
The Type 2 Diabetes (Metabolic Disorders)
pipeline guide also reviews of key players involved in therapeutic development
for Type 2 Diabetes and features dormant and discontinued projects. The guide
covers therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Pre-Registration, Filing
rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical,
Discovery and Unknown stages are 14, 1, 25, 68, 64, 5, 250, 75 and 6
respectively. Similarly, the Universities portfolio in Phase II, Phase I,
IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 22
molecules, respectively.
Type 2 Diabetes (Metabolic Disorders) pipeline
guide helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage. The guide is built
using data and information sourced from proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
Request A Sample copy of This
Report @
Note: Certain content / sections in the
pipeline guide may be removed or altered based on the availability and
relevance of data.
Scope
·
The pipeline
guide provides a snapshot of the global therapeutic landscape of Type 2
Diabetes (Metabolic Disorders).
·
The pipeline
guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)
by companies and universities/research institutes based on information derived
from company and industry-specific sources.
·
The pipeline
guide covers pipeline products based on several stages of development ranging
from pre-registration till discovery and undisclosed stages.
·
The pipeline
guide features descriptive drug profiles for the pipeline products which
comprise, product description, descriptive licensing and collaboration details,
R&D brief, MoA & other developmental activities.
·
The pipeline
guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders)
therapeutics and enlists all their major and minor projects.
·
The pipeline
guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on
mechanism of action (MoA), drug target, route of administration (RoA) and
molecule type.
·
The pipeline
guide encapsulates all the dormant and discontinued pipeline projects.
·
The pipeline
guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes
(Metabolic Disorders)
Reasons to
buy
1. Procure strategically important competitor
information, analysis, and insights to formulate effective R&D strategies.
2. Recognize emerging players with potentially
strong product portfolio and create effective counter-strategies to gain
competitive advantage.
3. Find and recognize significant and varied
types of therapeutics under development for Type 2 Diabetes (Metabolic
Disorders).
4. Classify potential new clients or partners in
the target demographic.
5. Develop tactical initiatives by understanding
the focus areas of leading companies.
6. Plan mergers and acquisitions meritoriously by
identifying key players and it's most promising pipeline therapeutics.
7. Formulate corrective measures for pipeline
projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth
and focus of Indication therapeutics.
8. Develop and design in-licensing and
out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope.
9. Adjust the therapeutic portfolio by
recognizing discontinued projects and understand from the know-how what drove
them from pipeline.
Browse More Pharmaceuticals
& Healthcare Related Market Research Reports:
• Homozygous
Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2017 -
• Axial Spondyloarthritis - Pipeline Review, H1
2017 -
• Ankylosing
Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2017 -
http://www.hexareports.com/report/ankylosing-spondylitis-bekhterev-s-disease-pipeline-review-h1-2017
